3/27
07:25 am
genb
Generate Biomedicines (GENB) was upgraded by Zacks Research to "hold".
High
Report
Generate Biomedicines (GENB) was upgraded by Zacks Research to "hold".
3/24
09:00 am
genb
Generate Biomedicines (GENB) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating and a $26.00 price target on the stock.
Medium
Report
Generate Biomedicines (GENB) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating and a $26.00 price target on the stock.
3/24
09:00 am
genb
Generate Biomedicines (GENB) is now covered by Morgan Stanley. They set an "overweight" rating and a $20.00 price target on the stock.
Medium
Report
Generate Biomedicines (GENB) is now covered by Morgan Stanley. They set an "overweight" rating and a $20.00 price target on the stock.
3/24
09:00 am
genb
Generate Biomedicines (GENB) is now covered by Piper Sandler. They set an "overweight" rating and a $24.00 price target on the stock.
Medium
Report
Generate Biomedicines (GENB) is now covered by Piper Sandler. They set an "overweight" rating and a $24.00 price target on the stock.
3/24
08:03 am
genb
Generate Biomedicines (GENB) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Generate Biomedicines (GENB) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/24
08:03 am
genb
Generate Biomedicines (GENB) is now covered by Guggenheim. They set a "buy" rating and a $30.00 price target on the stock.
Medium
Report
Generate Biomedicines (GENB) is now covered by Guggenheim. They set a "buy" rating and a $30.00 price target on the stock.
3/14
01:32 am
genb
Medium
Report
2/26
07:58 pm
genb
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
High
Report
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering